3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
3
Thoracic
2
Dermatologic
2
Gastrointestinal
1
Breast
1
Conditions
Uveal Melanoma
1
Squamous Cell Carcinoma of Head and Neck
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
49
Nivolumab
21
Cisplatin
11
Cetuximab
11
Carboplatin
10
Paclitaxel
8
Gemcitabine
8
Docetaxel
8
atezolizumab
7
Ipilimumab
7
Cyclophosphamide
7
spartalizumab
6
durvalumab
6
Fluorouracil
6
Capecitabine
6
fludarabine
5
avelumab
5
Albumin-Bound Paclitaxel
5
cemiplimab
4
Trastuzumab
4
Taxes
4
Oxaliplatin
4
Leucovorin
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
tremelimumab
3
tisotumab vedotin
3
aldesleukin
3
Specimen Handling
3
Interleukin-2
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Toll-Like Receptor 1
×
Gastrointestinal
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled